Total Payments
$1.3M
2024 Payments
$784.11
Companies
44
Transactions
1,643
Medicare Patients
2,438
Medicare Billing
$2.0M
Payment Breakdown by Category
Other$927,285 (72.2%)
Consulting$178,740 (13.9%)
Travel$107,697 (8.4%)
Research$39,511 (3.1%)
Food & Beverage$30,448 (2.4%)
Education$1,103 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $917,925 | 360 | 71.4% |
| Consulting Fee | $178,740 | 53 | 13.9% |
| Travel and Lodging | $107,697 | 319 | 8.4% |
| Unspecified | $39,511 | 73 | 3.1% |
| Food and Beverage | $30,448 | 814 | 2.4% |
| Honoraria | $7,360 | 5 | 0.6% |
| Charitable Contribution | $2,000 | 1 | 0.2% |
| Education | $1,103 | 18 | 0.1% |
Payments by Type
General
$1.2M
1,570 transactions
Research
$39,511
73 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $505,016 | 563 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $180,740 | 264 | $0 (2024) |
| EMD Serono, Inc. | $146,975 | 199 | $0 (2022) |
| Biogen, Inc. | $84,298 | 84 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $50,438 | 62 | $0 (2022) |
| Genentech USA, Inc. | $48,839 | 58 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $47,141 | 75 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $45,897 | 47 | $0 (2019) |
| Celgene Corporation | $38,389 | 50 | $0 (2023) |
| Horizon Therapeutics plc | $37,376 | 32 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $784.11 | 31 | TG Therapeutics, Inc. ($316.49) |
| 2023 | $12,058 | 27 | Biogen, Inc. ($9,638) |
| 2022 | $160,527 | 163 | Janssen Pharmaceuticals, Inc ($37,833) |
| 2021 | $98,743 | 126 | GENZYME CORPORATION ($25,111) |
| 2020 | $141,712 | 198 | EMD Serono, Inc. ($45,639) |
| 2019 | $285,712 | 357 | GENZYME CORPORATION ($111,460) |
| 2018 | $267,199 | 317 | GENZYME CORPORATION ($159,520) |
| 2017 | $318,051 | 424 | GENZYME CORPORATION ($192,461) |
All Payment Transactions
1,643 individual payment records from CMS Open Payments — Page 1 of 66
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: Immunology | ||||||
| 12/20/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: Immunology | ||||||
| 12/11/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $19.42 | General |
| 11/25/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Rare Disease | ||||||
| 11/19/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: Immunology | ||||||
| 10/18/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: Immunology | ||||||
| 10/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $30.84 | General |
| Category: Immunology | ||||||
| 10/02/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: Neurology | ||||||
| 09/17/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: Neurology | ||||||
| 09/06/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: Immunology | ||||||
| 08/28/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $31.28 | General |
| Category: Immunology | ||||||
| 08/22/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: Immunology | ||||||
| 08/13/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: Neurology | ||||||
| 08/08/2024 | Cycle Pharmaceuticals Inc | Tascenso ODT (Drug) | Food and Beverage | In-kind items and services | $45.65 | General |
| Category: NEUROLOGY | ||||||
| 08/06/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 07/30/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 07/10/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 06/12/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 06/11/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: Immunology | ||||||
| 06/05/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $16.04 | General |
| Category: NEUROLOGY | ||||||
| 06/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: Rare Disease | ||||||
| 05/29/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $101.82 | General |
| 04/24/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: Immunology | ||||||
| 04/24/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: Neurology | ||||||
| 04/11/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $8,750 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $7,800 | 11 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) | GENZYME CORPORATION | $6,079 | 18 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $3,913 | 17 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,473 | 2 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $1,575 | 5 |
| Case Study | GENZYME CORPORATION | $1,396 | 1 |
| A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients With Relapsing-Remitting Multiple Sclerosis | GENZYME CORPORATION | $1,250 | 1 |
| A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA Treatment In patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modif | GENZYME CORPORATION | $1,222 | 1 |
| A prospective observational cohort study in patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA (alemtuzumab) infusions of the first treatment course | GENZYME CORPORATION | $893.33 | 1 |
| A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $816.20 | 3 |
| An Extension Protocol for Multiple Sclerosis patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $512.25 | 3 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $497.14 | 3 |
| A prospective, 24-month observational study to evaluate patient reported outcomes and safety after Lemtrada treatment in patients with relapsing multipe sclerosis switching from a prior disease modify | GENZYME CORPORATION | $402.00 | 1 |
| A prospective, 24-month observational study to evaluate patient reported outcomes and safety after LEMTRADA treatment in patients with relapsing multiple sclerosis switching from a prior disease modif | GENZYME CORPORATION | $328.91 | 1 |
| A prospective, 24-month observational study to evaluate patient reported outcomes and safety after lemtrada treatment in patients with relapsing multiple sclerosis switching from a prior disease modif | GENZYME CORPORATION | $289.09 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 119 | 175 | $65,175 | $17,251 |
| 2022 | 11 | 468 | 1,002 | $188,758 | $52,437 |
| 2021 | 20 | 932 | 21,379 | $3.2M | $934,468 |
| 2020 | 21 | 919 | 28,250 | $3.6M | $1.0M |
Total Patients
2,438
Total Services
50,806
Medicare Billing
$2.0M
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 100 | 153 | $58,905 | $15,488 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 22 | $6,270 | $1,763 | 28.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 174 | 349 | $134,365 | $38,496 | 28.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 47 | $13,395 | $3,385 | 25.3% |
| 70553 | Mri scan of brain before and after contrast | Office | 2022 | 38 | 38 | $11,780 | $2,831 | 24.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 21 | 22 | $7,744 | $1,934 | 25.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 15 | 31 | $5,487 | $1,472 | 26.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 20 | 68 | $5,032 | $1,281 | 25.5% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2022 | 30 | 282 | $3,190 | $1,215 | 38.1% |
| 72156 | Mri scan of upper spinal canal before and after contrast | Office | 2022 | 13 | 13 | $3,185 | $950.45 | 29.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 15 | 24 | $1,800 | $565.08 | 31.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 79 | 107 | $2,675 | $293.51 | 11.0% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2022 | 19 | 21 | $105.00 | $13.20 | 12.6% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2021 | 20 | 18,600 | $2.8M | $815,128 | 29.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 200 | 539 | $207,515 | $65,861 | 31.7% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 46 | 112 | $39,424 | $11,375 | 28.9% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 46 | 329 | $24,346 | $7,074 | 29.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 60 | 137 | $24,249 | $6,490 | 26.8% |
| 95813 | Measurement of brain wave activity (eeg) extended monitoring, 61-119 minutes | Office | 2021 | 18 | 19 | $20,045 | $6,040 | 30.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 54 | 70 | $19,950 | $5,779 | 29.0% |
| 70553 | Mri scan of brain before and after contrast | Office | 2021 | 45 | 45 | $13,950 | $3,621 | 26.0% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2021 | 63 | 806 | $9,068 | $3,220 | 35.5% |
| 72156 | Mri scan of upper spinal canal before and after contrast | Office | 2021 | 29 | 29 | $7,105 | $2,191 | 30.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $6,576 | $2,033 | 30.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 37 | 68 | $5,100 | $1,684 | 33.0% |
About Samuel Hunter, M.D., PH.D
Samuel Hunter, M.D., PH.D is a Neurology healthcare provider based in Spring Hill, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093808107.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Samuel Hunter, M.D., PH.D has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $784.11 received in 2024. These payments were reported across 1,643 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($917,925).
As a Medicare-enrolled provider, Hunter has provided services to 2,438 Medicare beneficiaries, totaling 50,806 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Clinical Neurophysiology, Neuroradiology
- Location Spring Hill, TN
- Active Since 10/02/2006
- Last Updated 04/19/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1093808107
Products in Payments
- LEMTRADA (Drug) $265,455
- AUBAGIO (Drug) $212,715
- GILENYA (Drug) $90,907
- Mavenclad (Drug) $71,195
- Mavenclad (Biological) $63,713
- ACTHAR (Biological) $59,761
- VUMERITY (Drug) $57,415
- OCREVUS (Biological) $49,008
- ZEPOSIA (Drug) $47,460
- Ponvory (Drug) $37,923
- UPLIZNA (Drug) $37,376
- MAYZENT (Drug) $27,109
- COPAXONE (Drug) $24,433
- NO PRODUCT DISCUSSED (Drug) $19,934
- Soliris (Drug) $8,843
- TYSABRI (Biological) $8,802
- Betaseron (Drug) $8,405
- Ozanimod (Drug) $6,925
- KESIMPTA (Drug) $6,475
- Non-Covered $6,251
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.